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Background: Several randomized clinical trials (RCTs) indicate that flavanol-rich chocolate has beneficial effects on
flow-mediated dilation (FMD) and blood pressure (BP). However, no RCTs have evaluated these outcomes in
pregnant women. The objective of this 2-group, parallel, double-blind RCT was to examine the effects of flavanol-
rich chocolate on FMD and BP in pregnant women with normal BP.
Methods: Forty-four healthy, pregnant women were randomized to the high-flavanol (n = 23) or low-flavanol
(n = 21) chocolate consumption for 12 weeks. At randomization (0, 60, 120 and 180 min after a single 40-g dose of
chocolate), 6 and 12 weeks after daily 20-g chocolate intake, we evaluated plasma concentrations of flavanols and
theobromine, as well as the FMD and BP.
Results: Plasma epicatechin was significantly increased (p < 0.001) 180 min after the consumption of 40-g high-
flavanol chocolate compared to low-flavanol chocolate. Theobromine concentrations were significantly higher
180 min and 12 weeks after the intake of experimental chocolate or low-flavanol chocolate (p < 0.001). FMD was
not different between the 2 groups at all pre-defined time periods. No other significant within-group or between-
group changes were observed.
Conclusion: These results confirm the feasibility of a large-scale RCT comparing daily consumption of flavanol-rich
chocolate to an equivalent placebo during pregnancy and demonstrate higher plasma epicatechin and
theobromine concentration in the intervention group after acute ingestion
Trial registration: ClinicalTrials.gov Identifier: NCT01659060
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reproduction in any medium, provided the orespecially in developing countries [2]. It is estimated that
3 to 8% of all pregnancies are impacted by this compli-
cation. Every year, PE is responsible for about 60,000
deaths worldwide [1]. More than half of women with PE
will undergo caesarean delivery [1]. PE heightens the risk
of peri-natal mortality by 5-fold and is a major cause of
low birth weight in infants [1]. Numerous studies have
suggested that women who develop PE have an in-
creased risk of cardiovascular disease later in life [3].
The cardiovascular manifestations of PE share many
characteristics and risk factors with cardiovascularral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion and oxidative stress [4,5].
Despite intensive research, PE remains an idiopathic
disease for which few effective prophylactic measures
are available to patients [2]. PE is associated with a
placental disease in most cases and is distinguished by
generalized maternal dysfunction of the endothelium.
Endothelium dysfunction leads to clinical symptoms in
the mother [6,7]. There is strong evidence that maternal
nitric oxide (NO) deficiency plays a key role in the
development of PE [8]. Therapeutic approaches focusing
on up-regulating NO availability may be useful targets in
PE prevention. Flavanols, the most common flavonoids
in dark chocolate, are potent antioxidants capable of
inducing NO-dependent vasodilation. A recent meta-
analysis of randomized controlled trials (RTCs) confirmed
that flavanol-rich chocolate has a beneficial influence on
endothelial function and reduces systolic (SBP) and dia-
stolic blood pressure (DBP) [9]. Recent cohort [10] and
case–control studies [11] have indicated that chocolate
consumption during pregnancy may lower the risk of PE,
but their design did not permit the exploration of temporal
relationships. Moreover, this association was not found in
another case–control study [12]. Finally, a non-placebo,
controlled, non-blinded study by Di Renzo et al [13]
suggested that modest daily intake of high-cocoa content
chocolate contributes to BP reduction during pregnancy.
As endothelial dysfunction is fundamental to PE devel-
opment we believe that the growing body of literature
supporting the hypothesis of a beneficial outcome of
flavanol-rich chocolate consumption, through its action
on endothelial function and BP regulation, justifies a
clinical trial in pregnant women.
The primary objective of this pilot RCT is to test the
feasibility of design methods and procedures for later
use on a larger scale. The secondary objective is to
examine the acute and chronic impact of dark chocolate




Protocol and consent form of this study was reviewed and
approved by the institutional Ethics Committee of Centre
Hospitalier Universitaire de Québec. An information and
consent form, approved by the institutional Ethics
Committee, was read and signed by the participants.
Study participants
Between July 2008 and April 2009, we enrolled non-
smoking, normotensive women aged 18 to 35 years, with
a live fetus between the 7th and 12th weeks of gestation
documented by ultrasound. Normal BP was defined as
SBP <140 mmHg and DBP <90 mmHg.We excluded patients with a family history of prema-
ture cardiovascular disease, chronic hypertension, renal
dysfunction, medication use for treating hypertension or
interfering with the metabolism of glucose or lipids,
taking supplements or natural health products that may
interfere with BP (fish oils, coenzyme Q10, and garlic).
Women consuming 1 alcoholic drink per day or more,
or suffering from allergies or intolerance to nuts or
chocolate were also excluded.
Recruitment and randomization
Women were recruited through advertisements given to
them by healthcare professionals previously informed
about the project. Those wishing to participate contacted
the Study Coordinator who explained the research
project to them. They then presented themselves at the
Research Center of Saint-François d’Assise Hospital for a
total of 4 visits.
The recruitment protocol included an initial visit dur-
ing which suitability for randomization was evaluated.
Inclusion and exclusion criteria as well as the risks and
benefits of the study were reviewed in detail during this
pre-randomization visit. An information and consent
form, approved by the institutional Ethics Committee,
was read and signed. BP was measured 3 times at 3-min
intervals and averaged, according to a validated protocol
[14]. Anthropometric measurements and fasting blood
samples were collected. The blood samples were analyzed
for lipid and fasting blood sugar profiles. A questionnaire
documenting social and demographic characteristics, to-
bacco use, consumption of alcohol and medications was
completed by all women which were also required to
complete a 3-day food record [15], including a weekend
day, and a validated 2-day activity record [16,17] the week
before the 2nd visit. Nutrient and food intake results were
evaluated with the Nutrition Data System for Research,
version 4.03, developed by the Nutrition Coordinating
Center, University of Minnesota in Minneapolis.
Eligible healthy, pregnant women were randomly
assigned to either high-flavanol dark chocolate (experi-
mental group) or low-flavanol dark chocolate (placebo
group). Concealed randomization was generated using
computer-aided block randomization (block size was kept
secret), with pre-stratification by parity and body mass
index (BMI), under the responsibility of an independent
statistician. Another statistician undertook treatment
allocation independently of the trial team. At the
randomization visit participants were instructed to
consume in the fasting state 40-g of chocolate within
10 min. The composition of each chocolate bar – energy,
nutrients, catechins, epicatechins and theobromine – was
quantified by Barry Callebaut (Lebbeke-Wieze, Belgium)
and re-evaluated before the beginning of the study at the
INAF Laboratory using mass spectrometry (Table 1). All
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theobromine content and matched for caloric load, nutri-
ents and caffeine. All of them were similar in taste and
were supplied free in individual, opaque packaging by
Barry Callebaut. Our cocoa provided 400 mg of total
flavanols. Therefore, to isolate the effects of flavanols, our
chocolate placebo was identical to the experimental
chocolate in its content for all other nutrients except for
flavanols (including theobromine and caffeine contents).Clinical follow-up
During the chronic phase, the women were advised
to consume chocolate bars 3 times a day for a total
of 20-g daily providing 400 mg of total flavanols and
64 mg of epicatechin and catechin. This flavanol
daily intake should be sufficient to exert beneficial
effects. Indeed, in a similar study of non-pregnant
women, a chronic consumption of 373 mg flavanol
content was associated with significant outcomes on
BP and endothelial function. Moreover, its caloric
value was easily replaced by a snack of equivalent
energy. Therefore, the balance between beneficial ef-
fects, caloric value and fat content was carefully
considered.
Participants were scheduled for 2 follow-up visits at 6
and 12 weeks after randomization. All clinical investiga-
tions, laboratory analyses, data collection and assessment
were blinded to the randomization allocation.
The participants were asked not to consume other
chocolate products during the study and to avoid
foods rich in polyphenols or theobromine (tea, cof-
fee, fruit juice, wine) for 24 h before each visit. In-
tense physical activity was also forbidden for 48 h
preceding each visit. Anthropometric measurements
were taken at each visit, and the participants com-
pleted a food frequency questionnaire (FFQ) specific-
ally evaluating their polyphenol consumption in theTable 1 Chocolate composition (20 g)
Components High-flavanol Low-flavanol
chocolate chocolate
Energy (kcal) 102 102
Total fat (g) 7.5 7.5
Carbohydrates (g) 6.5 6.5
Protein (g) 1.35 1.35
Total flavanols (mg) 400 <60
Total catechin + epicatechin (mg) 64 14
Caffeine (mg) 23.6 23.6
Theobromine (mg) 150 150last month. Blood samples were collected, and FMD
and BP were quantified.
Endpoints
FMD
The primary endpoint was change in endothelial function,
measured as FMD of the brachial artery, as described previ-
ously [18,19]. A compact ultrasound system – LOGIQe
from GE Healthcare Technology, and Brachial Analyser
version 5 software – recorded these measurements. Accur-
acy and reproducibility were measured previously by other
groups [20] and the coefficients of variation were 9.8%,
10.6%, 6.6%, and 9.2% at 4–6 hours, 1 week, 1 month, and
3 months, respectively. The test was performed by the same
experienced technician in a quiet, dimly-lit room, between
08:00 and 12:00 h (noon). Ambient temperature was com-
fortable and constant (23.5°C). Before each measurement,
the women lay on their back, in a comfortable position,
with the arms and feet uncrossed for 15 min. They were
encouraged to avoid speaking. The right arm was extended
laterally for measurement at a 90-degree angle to the body.
The forearm was slightly supine in a comfortable position.
Depth was programmed and parameters were adjusted to
obtain an optimal view of the anterior and posterior walls
of the brachial artery. The ultrasound probe was positioned
precisely.
Once these parameters were optimized and the probe
position noted, they were recorded and kept constant
throughout the study. The right brachial artery was
imaged longitudinally just above the antebrachial fossa,
and images were captured at the same moment in the
cardiac cycle (R wave peak).
BP
BP was measured by a trained, certified nurse blinded to
treatment allocation, with an electronic monitor (Microlife
3 BTO-A) after 15 min of rest, back supported, arm sup-
ported at the heart level, and cuff placed on the left upper
arm. The device achieved British Hypertension Society
(BHS) A/A grade accuracy and was validated in a pregnant
population, including PE, according to the BHS protocol
[14]. BP was measured 3 times at 3-min intervals at the
randomization visit and 0, 60, 120 and 180 min after choc-
olate bar intake. It was assessed with the same standardized
protocol at weeks 6 and 12.
Plasma biomarkers of chocolate intake
Methylxanthines (caffeine, theobromine and theophyl-
line) were simultaneously quantified by high-pressure
liquid chromatography (HPLC) [21], by a technician
blinded to participant status. Inter- and intra-assay coef-
ficients of variation were 5.2% and 3.7%, respectively.
Plasma flavanol concentrations were measured with
standard analysis equipment. Flavanols were purified by
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detection system [22].
Side-effects
Weight change was evaluated at each visit, and digestive
and other signs and symptoms (nausea, abdominal pain,
constipation, and headache) were documented with a
self-administered questionnaire related to the week pre-
ceding the visit.
Compliance
Each participant received a telephone reminder in the
week preceding each visit. Women were paid an alloca-
tion for expenses related to the assessment visits. If a
participant missed a visit, the nurse scheduled a new
appointment. In addition, study participants recorded
their daily intake of chocolate bars on diary cards.
Blinding and contamination bias
The proportion of women who guessed right about
group allocation was documented with a short question-
naire at the last visit. To control for contamination bias,
the flavonoid consumption was measured by FFQ in the
last month preceding each follow-up visit.
Sample size and statistical analysis
Changes in FMD were defined as a primary endpoint
calculated as variations 12 weeks after chocolate intake
and expressed as mean differences. The secondary out-
come was BP. All analyses were based on intention-to
-treat. In the context of this feasibility study, no sample
size was calculated and the 44 pregnant women who
agreed to participate were included on the basis of rec-
ommendations by Thabane et al [23].
The baseline characteristics of the 2 groups were
compared, and factors influencing BP were considered
descriptively. Non-paired t tests were performed for
planned comparisons between groups. Changes within
groups were evaluated by paired t test. P ≤ 0.05 values
were considered as significant. The presence of side-
effects was compared in the 2 groups.
Results
We approached 176 women, of whom 27 were excluded
as they failed to meet the inclusion criteria: 12 were over
16 weeks pregnant, 6 were smokers, 5 had a body mass
index >30, 4 did not meet other criteria, and 5 had
spontaneous abortions (n = 5). One hundred women
declined to participate for different reasons: 72 women
had logistical or personal problems (transportation,
work, other children at home, too time-consuming), 18
did not return calls, and 10 refused to give a reason for
withdrawing their participation. Finally, 44 (33%) of the
132 pregnant women who met the inclusion criteria andwho agreed to participate were randomised (23 in the
high-flavanol chocolate arm and 21 in the low-flavanol
chocolate arm) (Figure 1). The baseline characteristics of
the women who declined to participate were not signifi-
cantly different from those of randomised women (data
not included). At randomization, the 2 arms were well
balanced with regard to social and baseline characteris-
tics (Tables 2 and 3).
Of the 44 randomized women who participated in the
acute phase, 42 (22 and 20 in the high-flavanol and low-
flavanol chocolate arms, respectively) had outcomes
available for intention-to-treat analysis. Two women
dropped out of the study for reasons not related to the
intervention.
Plasma biomarkers of chocolate intake
Plasma epicatechin concentrations increased signifi-
cantly in the high-flavanol chocolate group at 180 min
after intervention compared to low-flavanol chocolate
(p < 0.001) (Table 4). This dose of high-flavanol choc-
olate in the current study had no effect on increasing
plasma catechin concentrations. After 12 weeks,
epicatechin and catechin concentrations were too low
to be detectable.
As expected, methylxanthine concentrations were sig-
nificantly higher at 180 min compared to baseline in the
2 groups (Table 5). More specifically, a significant
increase in plasma theobromine concentrations was ob-
served in both groups at 180 min and was slightly but
significantly more marked in the experimental group.
Therefore, theobromine concentrations served as a
marker of chocolate compliance. A significant difference
in caffeine concentrations (p = 0.02) was also seen in the
two chocolate groups after single chocolate intake.
Compared to baseline, theobromine concentrations
were still significantly higher in high-flavanol and low-
flavanol chocolate groups at 6 and 12 weeks, indicating
good subject compliance (Table 6). A small but signifi-
cant difference in plasma theobromine concentrations
(p = 0.03) was noted between chocolate groups after
12 weeks of chocolate consumption.
FMD and BP
FMD, SBP, DBP and mean arterial BP (MAP) were not
significantly affected by acute or chronic consumption of
high-flavanol chocolate, as reported in Tables 7 and 8.
No significant changes were observed within or be-
tween groups for SBP after 6 or 12 weeks. Although
within normal values, DBP increased significantly from
baseline after 6 and 12 weeks only in the low-flavanol
chocolate group, but the difference between the 2 groups
was not significant. At 12 weeks, MAP rose significantly
in the low-flavanol chocolate group compared to base-


























Excluded (n = 132)





(n = 100) 
Dark chocolate (n = 23)
23 received intervention as 
randomized
Placebo chocolate (n = 21)
21 received intervention as 
randomized
Acute phase
21 included in analysis
Acute phase
23 included in analysis
Chronic phase 
Lost to follow-up (n = 1)
1 withdrew voluntarily
Chronic phase




22 included in analysis
Chronic phase 
Lost to follow-up (n = 2) 
1 had headache
1 discontinued intervention* 
Acute phase
0 lost to follow-up
Acute phase
0 lost to follow-up
Figure 1 Flow diagram of study participants. *The participant withdrew voluntarily from the study without giving a reason, but accepted
to return.
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served between or within groups.Side-effects
High-flavanol and low-flavanol chocolate did not signifi-
cantly increase the intake of energy, proteins, carbohy-
drates and fats after 12 weeks of chocolate consumption
(Tables 9). Total energy consumed by pregnant women
was similar in both groups. A significant decrease in the
percentage of calories from proteins in the low-flavanol
chocolate group (difference: -1.7; 95% CI: -2.8 to −0.5)
was apparent after the intervention (Table 9). The
contribution of other macronutrients to total energy
intake did not change over time for any of the two
groups studied.In both arms, body weight and body mass index (BMI)
increased significantly after chocolate consumption for
12 weeks (Table 10), but no significant differences in these
parameters were observed between the high-flavanol and
low-flavanol chocolate arms.
Discussion
In healthy, pregnant women with normal BP and with-
out risk of PE, acute and chronic consumption of
flavanol-rich chocolate was not associated with signifi-
cant changes in either FMD, SBP or DBP. Our clinical
study provides important insights into the feasibility,
acceptability and methodology of a larger clinical trial
to evaluate long-term chocolate intake in pregnant
women. Our results confirmed the feasibility and good
compliance of our intervention and its effectiveness in
Table 2 Demographic characteristics
Characteristics High-flavanol chocolate (n = 23) Low-flavanol chocolate (n = 21)
Marital status
Common-law spouse 19 (82.6) 15 (71.4)
Married 4 (17.4) 6 (28.6)
Number of children
0 14 (60.9) 13 (61.9)
1 7 (30.4) 6 (28.6)
2 2 (8.7) 1 (4.8)
3 0 1 (4.8)
Educational attainment
University degree 17 (73.9) 15 (71.4)
College or trade certification 5 (21.7) 4 (19.1)
Some university education 0 1 (4.8)
Some college education 0 1 (4.8)
High school diploma 1 (4.4) 0
Women with paid work* 23 (100) 19 (90.5)
Average hours worked (per year)˦ 1,717.1 ± 482.7 1,817.5 ± 503.9
(n = 22) (n = 19)
Perception of financial situation ˦˦
Sufficient income 13 (56.5) 13 (61.9)
Low income 10 (43.5) 8 (38.1)
Regular alcohol consumption ˦˦˦ 4 (17.4) 1 (4.8)
Smoker˦˦˦ 0 1 (4.8)
* During the past year Number (percentage).
˦ Values are means ± SD.
˦˦ Perception of women compared to people of their age.
˦˦˦ In the last month.
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concentrations after acute ingestion.
The association between chocolate consumption and
the risk of PE was explored for the first time in a cohort
study [10] of 2,291 pregnant North American women
who gave birth to a single, living baby. “Exposure” to
chocolate was measured in 2 ways: data on the provision
of caffeine-rich drinks and chocolate consumption since
the beginning of pregnancy were collected during a
structured interview around the 14th week of gestation.
Consumption was also evaluated during the 3rd trimes-
ter of pregnancy in a post-natal interview. On the other
hand, the serum concentrations of theobromine were
quantified in a blood sample collected from the umbil-
ical cord during delivery. Serum theobromine concentra-
tions were inversely correlated with the risk of PE before
and after adjustment for the main confounding factors
(odds ratio (OR) = 0.31; 95% CI: 0.11 - 0.87, for the
highest compared to the lowest quartile). Women who
consumed 5 or more portions of chocolate per week
during the 3rd trimester of pregnancy manifested a 40%
decrease in PE risk compared to women who consumedless than 1 portion of chocolate per week (OR = 0.60;
95% CI: 0.30 - 1.24). However, this diminution was not
significant. A case–control study [12] nested in a cohort
does not support the previous finding. According to the
authors, unmeasured confounding or reverse causation
may account for the positive association previously
reported as discussed above. A non-placebo, controlled,
non-blinded study by Di Renzo et al [13] suggested that
modest daily intake of high-cocoa content chocolate
contributes to BP reduction during pregnancy. The
results of these epidemiologic studies reinforce the im-
portance to assess the effect of chocolate consumption
using a clinical trial design.
In our study, DBP increased significantly from baseline
to 12 weeks in the high-flavanol and low-flavanol choc-
olate groups, but the difference between the 2 groups
was not significant. It is probable that this elevation was
related to the normal increases from the second to the
third trimester of pregnancy.
Although no prospective studies in pregnant women
are available, the effects of daily flavanol-rich chocolate
intake on endothelial function and BP have already been
Table 3 Baseline characteristics of 44 pregnant women by study arm
Baseline characteristics High-flavanol chocolate (n = 23) Low-flavanol chocolate (n = 21)
Age (years) 28.7 ± 3.17 29.76 ± 3.63
Height (m) 1.64 ± 0.06 1.66 ± 0.04
Weight (kg) 66.07 ± 6.79 64.90 ± 8.14
BMI (kg/m2) 24.73 ± 2.68 23.61 ± 2.85
Gestation duration at randomisation (weeks) 21.13 ± 1.10 21.10 ± 1.61
Blood pressure
Systolic blood pressure (mmHg)* 109.43 ± 7.65 105.94 ± 7.84
Diastolic blood pressure (mmHg)* 66.80 ± 6.34 64.23 ± 6.24
Mean arterial pressure (mmHg)* 81.01 ± 5.87 78.14 ± 6.48
Flow-mediated dilation (%) 11.86 ± 4.66 13.25 ± 3.80
Plasma biomarkers of chocolate intake
Theobromine (μg/mL plasma) 0.45 ± 0.43 0.35 ± 0.37
Theophylline (μg/mL plasma) 0.13 ± 0.18 0.07 ± 0.11
Caffeine (μg/mL plasma) 0.58 ± 0.82 0.29 ± 0.46
Plasma flavanol concentrations
Epicatechin (ng/mL plasma) 4.90 ± 0.00 4.90 ± 0.00
Catechin (ng/mL plasma) 55.99 ± 44.23 44.05 ± 46.68
*Average of 3 measurements Values are means ± SD.
Table 4 Acute changes in the plasma concentrations of
biomarkers after single dose chocolate intake





(n = 21) (n = 23)
Epicatechins (ng/mL)
0 min (Baseline) 4.90 ± 0.00 4.90 ± 0.00 -
180 min 4.90 ± 0.00 97.02 ± 41.94 <0.0001
P value (180 vs. 0 min) - <0.0001
Catechins (ng/mL)
0 min (Baseline) 44.05 ± 46.68 55.99 ± 44.23 -
180 min 43.62 ± 42.88 59.11 ± 43.50 0.70
P value (180 vs. 0 min) 0.92 0.70
Values are means ± SD.
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recent meta-analysis by Hooper et al., that included 11
studies and 373 participants, suggested improvement of
FMD 2 h after chocolate ingestion and its chronic intake
[26]. Stronger effects were apparent at higher doses of
epicatechin that could be a key contributor to the out-
comes observed. They also found a significant effect of
chocolate on DBP and MAP but heterogeneity of the
results of the 11 studies included in this meta-analysis
was significant. This heterogeneity could be partially
explained by BP differences in participants at the start of
chocolate intake. Indeed, recent investigations have
reported unchanged [27] or no significant change [28] in
SBP and DBP after dark chocolate consumption in
normotensive, healthy populations. Taubert et al., in
their meta-analysis, observed trends towards a marked
effect of chocolate intake in patients with high BP [29].
In our clinical trial, although acute ingestion of our ex-
perimental chocolate bars was accompanied by a very
significant increase in plasma epicatechin concentra-
tions, daily, chronic epicatechin intake by pregnant
women could have been too low to improve BP. In fact,
in the meta-analysis by Hooper et al [26], subgroup ana-
lysis by epicatechin dose suggested greater effects on BP
at doses exceeding 50 mg, but not with doses less than
50 mg. In our study, pregnant women had to consume
20-g of chocolate daily, which provided less than 50 mg
of epicatechin if all chocolate bars provided were eaten.
Other investigations also showed an increment
in plasma epicatechin concentrations after acuteconsumption of flavanol-rich products [30-32]. The
amount of experimental chocolate administered in our
study had no effect on increasing plasma catechin
concentrations. Similar observations have been made
previously [30,31]. Epicatechin is the predominant
flavanol in dark chocolate. Moreover, among the
flavanols, epicatechin has been reported to occur in a
primary bioavailable form [33]. Holt et al [32] sug-
gested that complex mixtures of chocolate dimers and
oligomers may be degraded in the gut into epicatechin
monomers, which promotes absorption and would ex-
plain the low catechin concentrations in plasma.
Table 5 Acute changes in methylxanthine concentrations
after single-dose chocolate intake





(n = 21) (n = 23)
Theobromine (μg/mL)
0 min (baseline) 0.35 ± 0.37 0.45 ± 0.43 -
180 min 5.47 ± 1.29 6.51 ± 0.80 0.0122
P value (180 vs. 0 min) <0.0001 <0.0001
Theophylline (μg/mL)
0 min (Baseline) 0.07 ± 0.11 0.13 ± 0.18 -
180 min 0.12 ± 0.12 0.18 ± 0.13 0.85
P value (180 vs. 0 min) <0.0001 0.0009
Caffeine (μg/mL)
0 min (Baseline) 0.29 ± 0.46 0.58 ± 0.82 -
180 min 1.07 ± 0.50 1.54 ± 0.67 0.0201
P value (180 vs. 0 min) <0.0001 <0.0001
Values are means ± SD.
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tion. Blood sample extraction after a 12-h fast could
have been responsible for the low epicatechin concentra-
tions, considering that epicatechin clearance from the
plasma compartment is very fast [31] and most absorbed





Baseline 0.35 ± 0.37
Week 6 1.44 ± 0.73
Week 12 1.30 ± 0.69
P value (Week 6 vs. Baseline) <0.0001
P value (Week 12 vs. Baseline) <0.0001
Theophylline (μg/mL)
Baseline 0.07 ± 0.11
Week 6 0.24 ± 0.24
Week 12 0.17 ± 0.17
P value (Week 6 vs. Baseline) 0.0001
P value (Week 12 vs. Baseline) 0.0003
Caffeine (μg/mL)
Baseline 0.29 ± 0.46
Week 6 1.12 ± 1.27
Week 12 0.82 ± 1.15
P value (Week 6 vs. Baseline) 0.004
P value (Week 12 vs. Baseline) 0.02
Values are means ± SD.[30,34]. Moreover, Taubert et al [35] excluded the stor-
age of plasma phenols after dark chocolate intake be-
cause the short elimination half-lives of flavanols
prevented accumulation of plasma levels and thus no
flavanols could be detected after 12-h post-intake of
flavonoid-rich dark chocolate. Nevertheless, after daily
dietary chocolate incorporation for 12 weeks, even if
epicatechin concentrations were very low, plasma theo-
bromine increased 4-fold, indicating very good compli-
ance, as discussed below. Plasma epicatechin levels
should be quantified 2 h after the chocolate dose be-
cause of the short elimination half-life of flavanols.
The marginal but statistically-significant increase in
theobromine levels in the experimental compared to
placebo group at 180 minutes and 12 weeks post-
randomisation could be attributed to different rates of
intestinal metabolism, which is influenced by diet. In-
deed, orally-administered, theobromine is rapidly and
almost completely absorbed by the gastrointestinal tract
[31]. At baseline, theobromine concentrations were also
slightly lower in the placebo group, but its sources in
diet measured by FFQ in the last month preceding
randomisation and each follow-up visit, were not signifi-
cantly different between the 2 groups.
Some limitations [36] of the technique for FMD as-
sessment could also explain our lack of significant effect.
Measurement of endothelial function is challenging.ter daily consumption of 20-g chocolate






0.45 ± 0.43 -
1.82 ± 0.76 0.34
1.87 ± 0.85 0.03
<0.0001
<0.0001
0.13 ± 0.18 -
0.27 ± 0.29 0.66
0.27 ± 0.20 0.49
0.045
0.0076
0.58 ± 0.82 -
1.30 ± 2.08 0.78
1.56 ± 2.05 0.34
0.12
0.03
Table 7 Acute changes in FMD and BP after single dose
chocolate intake





(n = 21) (n = 23)
FMD (%)
0 min (baseline) 13.3 ± 3.8 11.9 ± 4.7 -
60 min 13.0 ± 4.3 10.2 ± 3.1 0.50
120 min 12.1 ± 3.0 10.8 ± 4.2 0.99
180 min 11.0 ± 2.8 11.6 ± 3.7 0.18
P value (60 vs. 0 min) 0.82 0.18
P value (120 vs. 0 min) 0.35 0.24
P value (180 vs. 0 min) 0.16 0.77
Systolic BP (mmHg)
0 min (baseline) 105.9 ± 7.8 109.4 ± 7.6 -
60 min 107.0 ± 5.7 110.3 ± 6.8 0.95
120 min 105.3 ± 6.0 110.0 ± 7.1 0.49
180 min 105.8 ± 5.7 108.7 ± 6.3 0.72
P value (60 vs. 0 min) 0.38 0.39
P value (120 vs. 0 min) 0.59 0.66
P value (180 vs. 0 min) 0.86 0.55
Diastolic BP (mmHg)
0 min (baseline) 64.2 ± 6.2 66.8 ± 6.3 -
60 min 64.2 ± 5.9 64.5 ± 5.1 0.07
120 min 64.0 ± 5.1 66.1 ± 5.6 0.68
180 min 64.2 ± 4.9 66.4 ± 5.1 0.81
P value (60 vs. 0 min) 0.98 0.01
P value (120 vs. 0 min) 0.73 0.36
P value (180 vs. 0 min) 0.94 0.68
Mean arterial BP (mmHg)
0 min (baseline) 78.1 ± 6.5 81.0 ± 5.9 -
60 min 78.5 ± 5.4 79.8 ± 5.2 0.16
120 min 77.8 ± 5.1 80.7 ± 5.7 0.92
180 min 78.0 ± 4.8 80.5 ± 4.9 0.73
P value (60 vs. 0 min) 0.72 0.08
P value (120 vs. 0 min) 0.64 0.69
P value (180 vs. 0 min) 0.90 0.52
Values are means ± SD.
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available, the most frequently-used method involving
FMD of the brachial artery with ultrasound imaging was
incorporated in our trial. This gold standard technique
is not easy and requires extensive sonographer training
as well as labour-intensive image analysis. Also, lack of
standardization could influence methodological reprodu-
cibility in follow-up studies, particularly among pregnant
women. Moreover, in this trial, we adopted M modeduring image acquisition of the brachial artery. However,
both M and A modes are applied to continuously meas-
ure brachial diameter, and these techniques may be sub-
ject to error due to tracking drift [36]. In addition, M
mode is more variable than B mode; thus, it is difficult
to maintain the positional stability of measurements
which must be performed at set time points (50 s), limit-
ing reproducibility and showing lower FMD as a result
[20]. Furthermore, 40 to 60 patients are typically needed
in a parallel-group study design to find significant im-
provement in FMD [36]. Sample size in our study was
likely too small to detect a significant difference between
the 2 groups with this method. More novel fingertip-
based methodologies, such as pulse amplitude tonome-
try, which has the potential advantage of an automated,
computerized analysis system that minimizes operator
dependency and inter-observer variability, would be
more appropriate in prospective studies.
It is relevant to point out and discuss the consumption
of low-flavanol chocolate bars as placebo to high-
flavanol chocolate bars. In fact, our placebo chocolate
probably did not have a neutral effect compared to ex-
perimental chocolate because it provided similar theo-
bromine concentrations [26]. Although the beneficial
outcome of chocolate on FMD and BP has been largely
associated with flavanols, a recent clinical trial indicated
that theobromine could be partly responsible for the BP-
lowering action of chocolate [37]. Our results could have
been masked by its effects, which would confirm the im-
portance of carefully selecting an adequate placebo.
Interestingly, after checking the medical records of
participants when the study ended, the pregnant women
high-flavanol chocolate group had not incurred any kind
of disease related to hypertension or PE, whereas a par-
ticipant in the low-flavanol chocolate group had PE dur-
ing late pregnancy (result not shown).
Important and significant theobromine concentrations,
a good marker of chocolate intake, and the count of un-
used chocolate bars confirmed good compliance with
the intervention during 12-week follow-up, which did
not differ across arms. This finding suggests that 20-g
chocolate bars could be incorporated in the usual diet of
pregnant women for as long as 12 weeks. Based on the
compliance difference reported by pregnant women
(97.6% vs. 93.6%, experimental and placebo group,
respectively) the slight difference at week 12 (p = 0.03)
between the concentrations of theobromine in the two
groups could reflect better compliance in the experimen-
tal group. Moreover, at baseline, the high-flavanol choc-
olate group had theobromine concentrations that tended
to be higher compared with the low-flavanol chocolate
group. Therefore, the experimental group could have
had a higher consumption of dietary sources of theobro-
mine from their regular diet at baseline and throughout
Table 8 Changes in FMD and BP after daily consumption of 20-g chocolate for 6 and 12 weeks





(n = 20) (n = 22)
FMD (%)
Baseline 13.3 ± 3.8 11.9 ± 4.7 -
Week 6 11.4 ± 3.4 10.8 ± 3.9 0.22
Week 12 13.1 ± 3.8 10.4 ± 3.4 0.43
P value (Week 6 vs. Baseline) 0.06 0.32
P value (Week 12 vs. Baseline) 0.95 0.18
Systolic BP (mmHg)
Baseline 105.9 ± 7.8 109.4 ± 7.6 -
Week 6 104.8 ± 6.0 109.4 ± 7.5 0.98
Week 12 106.1 ± 9.7 108.8 ± 8.9 0.49
P value (Week 6 vs. Baseline) 0.69 0.83
P value (Week 12 vs. Baseline) 0.66 0.60
Diastolic BP (mmHg)
Baseline 64.2 ± 6.2 66.8 ± 6.3 -
Week 6 65.4 ± 5.9 68.0 ± 5.0 0.51
Week 12 68.2 ± 6.9 70.5 ± 6.8 0.50
P value (Week 6 vs. Baseline) 0.05 0.42
P value (Week 12 vs. Baseline) 0.0007 0.01
Mean arterial BP (mmHg)
Baseline 78.1 ± 6.5 81.0 ± 5.9 -
Week 6 78.5 ± 5.6 81.8 ± 5.2 0.65
Week 12 80.9 ± 7.5 83.2 ± 7.1 0.45
P value (Week 6 vs. Baseline) 0.20 0.64
P value (Week 12 vs. Baseline) 0.0081 0.15
Values are means ± SD.
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avoid these foods.
Overall, 42 of 44 randomized pregnant women were
retained in our study, and only 1 participant was not
included in intention-to-treat analysis.
Weight increases linearly during the 2nd and 3rd tri-
mesters of pregnancy, but is associated with escalating
physiological weight in pregnancy. Mean gestational
weight gain by our pregnant study participants was in
accordance with new recommendations of the commit-
tee re-examining pregnancy weight guidelines [38].
Caloric intake and nutritional dietary composition did
not change significantly during the trial. Although
chocolate has high energy density and is perhaps recog-
nized as a fattening food, several studies [35,39-41] have
not discerned any weight increase after daily chocolate
intake. In our pilot RCT, participants in the 2 arms were
instructed not to add chocolate bars to their usual diet
but to use them by replacing foods of similar energy
and macronutrient composition. Moreover, to ensuresupport and motivation for adequate use of chocolate,
women were met individually by a dietitian who offered
global counseling. These strategies could have a favor-
able impact on weight gain during pregnancy. Therefore,
we can speculate that weight gain was not attributable
to chocolate intake.
The participants were in good health at baseline and
probably represented mainly females with an interest in
health and diet. Therefore we can speculate that it may
have contributed to reduce the possibility of a significant
chocolate intake effect on FMD and BP. Therefore, our
results may not be applicable to high-risk pregnant
women.
Conclusion
The results of this pilot RCT confirm the feasibility of a
large RCT and flag important methodological, physio-
logical and clinical elements that need to be taken into
account in large-scale clinical studies. Treatment com-
pliance by all participants was satisfactory. Consumption
Table 9 Differences in energy and macronutrient intakes after 12 weeks of chocolate consumption





(n = 20) (n = 22)
Total energy (Kcal)
Baseline 2,086 ± 329 2,320 ± 464 -
Week 12 2,178 ± 286 2,251 ± 465 0.18
P value (Week 12 vs. Baseline) 0.28 0.42
Proteins (g)
Baseline 88.3 ± 19.7 89.4 ± 18.2 -
Week 12 82.7 ± 13.8 85.0 ± 22.2 0.86
P value (Week 12 vs. Baseline) 0.12 0.39
Proteins (% energy)
Baseline 17.0 ± 2.6 15.6 ± 2.4 -
Week 12 15.3 ± 2.3 15.1 ± 2.2 0.86
P value (Week 12 vs. Baseline) 0.13 0.0078
Carbohydrates (g)
Baseline 272.2 ± 45.0 305.8 ± 62.8 -
Week 12 284.5 ± 38.1 297.6 ± 64.0 0.19
P value (Week 12 vs. Baseline) 0.33 0.39
Carbohydrates (% energy)
Baseline 52.5 ± 5.6 53.0 ± 5.3 -
Week 12 52.4 ± 3.7 53.0 ± 4.9 0.10
P value (Week 12 vs. Baseline) 0.92 0.99
Baseline 77.3 ± 17.6 89.2 ± 26.9 -
Week 12 83.2 ± 16.3 86.3 ± 23.1 0.25
P value (Week 12 vs. Baseline) 0.22 0.61
Lipids (% energy)
Baseline 33.1 ± 3.8 34.2 ± 5.2 -
Week 12 34.2 ± 3.5 34.3 ± 3.7 0.28
P value (Week 12 vs. Baseline) 0.35 0.92
Values are means ± SD.
Table 10 Body weight and BMI after chocolate consumption for 12 weeks





(n = 20) (n = 22)
Weight (kg)
Baseline 64.1 ± 7.5 66.6 ± 6.5 -
Week 12 70.2 ± 8.2 72.9 ± 7.2 0.74
P value (Week 12 vs. Baseline) <0.0001 <0.0001
BMI (kg/m2)
Baseline 23.3 ± 2.6 24.9 ± 2.6 -
Week 12 25.5 ± 2.9 27.2 ± 2.8 0.58
P value (Week 12 vs. Baseline) <0.0001 <0.0001
Values are means ± SD.
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nificant changes in FMD, SBP and DBP in pregnant
women with normal BP. We cannot rule out that failure
to improve could have been due to a ceiling effect.
We could hypothesize that the absence of effects was
attributable to our healthy, normotensive female popula-
tion, among whom only small changes in BP or FMD
were to be expected. Nevertheless, as our study results
did not show side-effects, it would be pertinent to
specifically investigate these outcomes of flavanol-rich
chocolate in pregnant women at high risk of PE.
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